Business Highlights, Financial Results, and Leadership Appointments - Analyst Notes on PDL BioPharma, bluebird, Osiris, Agios and Ophthotech

NEW YORK, May 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding PDL BioPharma, Inc. (NASDAQ: PDLI), bluebird bio, Inc. (NASDAQ: BLUE), Osiris Therapeutics, Inc. (NASDAQ: OSIR), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Ophthotech Corporation (NASDAQ: OPHT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2594-100free.

--
PDL  BioPharma,  Inc.  Analyst  Notes
On May 12, 2014, PDL BioPharma, Inc. (PDL BioPharma) reported its Q1 2014 financial results with total revenues of $139.7 million, up 52.1% YoY. Operating expenses totaled $16.5 million, compared with $7.2 million in Q1 2013. Net income for the quarter was $72.9 million, or $0.44 per diluted share compared to $53.5 million, or $0.36 per diluted share in Q1 2013. The Company stated that the increase in net income in the first quarter is primarily attributable to the increase in royalty revenues. The Company informed that it will provide its Q2 2014 revenue guidance in June 2014. The  full  analyst  notes  on  PDL  BioPharma  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2594-PDLI-19May2014.pdf

--
bluebird  bio,  Inc.  Analyst  Notes
On May 13, 2014, bluebird bio, Inc. (bluebird) reported its Q1 2014 financial results with revenues of $6.3 million compared to $1.1 million in Q1 2013. According to the Company, the increase in revenue was driven by a full quarter of revenue under bluebird's collaboration with Celgene Corporation. Total operating expenses were $17.0 million compared to $7.6 million in Q1 2013. Net loss for the period was $10.6 million, or $0.44 per share compared to Q1 2013 net loss of $6.5 million, or $19.94 per share. "The first quarter of 2014 has been very productive for bluebird bio," said Nick Leschly, Chief, bluebird. "We treated the first beta-thalassemia major subject in our U.S. based Northstar Study with LentiGlobin, opened an IND for our sickle cell disease study and we are now presenting preliminary beta-thalassemia major data at the upcoming European Hematology Association Congress." The  full  analyst  notes  on  bluebird  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2594-BLUE-19May2014.pdf

--
Osiris  Therapeutics,  Inc.  Analyst  Notes
On May 12, 2014, Osiris Therapeutics, Inc. (Osiris) reported its unaudited Q1 2014 financial results with product revenues of $10.1 million, compared to $4.1 million in Q1 2013. Net loss from continuing operations was $0.6 million compared to $0.3 million in Q1 2013. As of March 31, 2014, Osiris had $91.3 million of total assets. "Our focus on execution has driven this strong start to 2014," said Lode Debrabandere, Ph.D., President and CEO of Osiris. "Now, along with the addition of key leadership, we are poised to carry this momentum forward as we continue to grow every facet of our business." The  full  analyst  notes  on  Osiris  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2594-OSIR-19May2014.pdf

--
Agios  Pharmaceuticals,  Inc.  Analyst  Notes
On May 14, 2014, Agios Pharmaceuticals, Inc. (Agios) announced that Chris Bowden, M.D. has been appointed to the newly created position of Chief Medical Officer. The Company stated that in this role, he will oversee global clinical development and regulatory initiatives for Agios. "We are thrilled that Chris is bringing to Agios his strong industry and operational leadership at a time when our three oral, first-in-class product candidates are advancing in the clinic," said David Schenkein, M.D., CEO of Agios. "Chris has deep experience in oncology drug development, including the use and approval of companion diagnostics, which will prove valuable for our clinical development and registration strategies." The Company stated that Dr. Bowden holds more than 17 years of experience in clinical drug development. He was previously the Vice President, Product Development Oncology, Franchise Lead at Genentech, Inc. The  full  analyst  notes  on  Agios  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2594-AGIO-19May2014.pdf

--
Ophthotech  Corporation  Analyst  Notes
On May 13, 2014, Ophthotech Corp. (Ophthotech) reported its unaudited Q1 2014 financial results and provided an update on the Company's business. The Company Q1 2014 operating expenses were $20.7 million compared to $4.1 million in Q1 2013. Net loss attributable to common stockholders for the quarter was $20.7 million, or $0.64 per share compared to $6.4 million or $4.33 per share. As of March 31, 2014, the Company had cash, cash equivalents and marketable securities totaling $290.8 million. The  full  analyst  notes  on  Ophthotech  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2594-OPHT-19May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED